# Effect of Denosumab on Cellular Biomarkers in the Human Breast

> **NCT02099461** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 82 (actual)

## Conditions studied

- Healthy Volunteer, Female, Breast

## Interventions

- **DRUG:** Denosumab
- **PROCEDURE:** Percutaneous core needle breast biopsy

## Key facts

- **NCT ID:** NCT02099461
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2015-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02099461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02099461, "Effect of Denosumab on Cellular Biomarkers in the Human Breast". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02099461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*